217 related articles for article (PubMed ID: 20524689)
1. Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site.
Alzate-Morales JH; Vergara-Jaque A; Caballero J
J Chem Inf Model; 2010 Jun; 50(6):1101-12. PubMed ID: 20524689
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
Caballero J; Alzate-Morales JH; Vergara-Jaque A
J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
[TBL] [Abstract][Full Text] [Related]
3. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
4. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.
Wenglowsky S; Moreno D; Rudolph J; Ran Y; Ahrendt KA; Arrigo A; Colson B; Gloor SL; Hastings G
Bioorg Med Chem Lett; 2012 Jan; 22(2):912-5. PubMed ID: 22209462
[TBL] [Abstract][Full Text] [Related]
7. Non-oxime inhibitors of B-Raf(V600E) kinase.
Ren L; Wenglowsky S; Miknis G; Rast B; Buckmelter AJ; Ely RJ; Schlachter S; Laird ER; Randolph N; Callejo M; Martinson M; Galbraith S; Brandhuber BJ; Vigers G; Morales T; Voegtli WC; Lyssikatos J
Bioorg Med Chem Lett; 2011 Feb; 21(4):1243-7. PubMed ID: 21251822
[TBL] [Abstract][Full Text] [Related]
8. Insight into the structural features of pyrazolopyrimidine- and pyrazolopyridine-based B-Raf(V600E) kinase inhibitors by computational explorations.
Li Y; Han C; Wang J; Yang Y; Zhang J; Zhang S; Yang L
Chem Biol Drug Des; 2014 Jun; 83(6):643-55. PubMed ID: 24373283
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
Talele TT; McLaughlin ML
J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.
Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q
Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective pyrazole-based inhibitors of B-Raf kinase.
Hansen JD; Grina J; Newhouse B; Welch M; Topalov G; Littman N; Callejo M; Gloor S; Martinson M; Laird E; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4692-5. PubMed ID: 18676143
[TBL] [Abstract][Full Text] [Related]
14. Non-oxime pyrazole based inhibitors of B-Raf kinase.
Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
Yang Y; Qin J; Liu H; Yao X
J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
[TBL] [Abstract][Full Text] [Related]
17. The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study.
Fratev F; Jónsdóttir SO
J Mol Graph Model; 2010 Apr; 28(7):598-603. PubMed ID: 20093060
[TBL] [Abstract][Full Text] [Related]
18. An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors.
Xie H; Li Y; Yu F; Xie X; Qiu K; Fu J
Int J Mol Sci; 2015 Nov; 16(11):27350-61. PubMed ID: 26580609
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.
Gökhan-Kelekçi N; Simşek OO; Ercan A; Yelekçi K; Sahin ZS; Işik S; Uçar G; Bilgin AA
Bioorg Med Chem; 2009 Sep; 17(18):6761-72. PubMed ID: 19682910
[TBL] [Abstract][Full Text] [Related]
20. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
